BioSpace News Archive

Ascendis Pharma A/S (Nasdaq: ASND), today announced the submission of an investigational new drug (IND) application with the U.S. Food & Drug Administration (FDA) to initiate IL βelieγe (I’ll Believe) Trial, a phase 1/2 clinical trial to evaluate TransCon IL-2 β/γ in patients with advanced cancer.

LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, today announced that members of the management team will present at the Morgan Stanley Global Healthcare Conference on Monday, September 13, 2021.

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it will be participating in Citi’s 16th Annual BioPharma Virtual Conference being held on September 8-10, 2021 and at the H.C. Wainwright Global Investment Conference.

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released business highlights and financial results for its fiscal year ended May 31, 2021.

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following virtual conferences in September.

Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces positive topline results from the U.S. Phase I trial of drug-drug interactions in healthy subjects and pharmacokinetics (PK) in patients with non-alcoholic fatty liver disease (NAFLD) for ASC41 oral tablets, a liver-targeted prodrug.

EnGeneIC Limited, an Australian, Sydney-based biotechnology company, has developed a globally unique nanocellular technology that in pre-clinical animal studies has been shown to stimulate a broad and powerful anti-COVID-19 immune response and also neutralises the known mutant COVID-19 viruses of concern, particularly the delta variant.

Biocept, a leading provider of molecular diagnostic assays and services, announces that Michael Nall, President and CEO, will present at four upcoming investor conferences.

Flash Therapeutics, a CDMO with strong technological expertise, is accelerating the ramp-up of its biomanufacturing capabilities.

AFYX Therapeutics announced results from a preclinical study from the company’s collaboration with the University of Sheffield in the UK exploring the potential effects of delivering antibody fragments directly to inflamed tissue in mucosal diseases using Rivelin® technology.